Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Article English OPEN
Jin, J.; Tarrant, R.D.; Bolam, E.J.; Angell-Manning, P.; Soegaard, M.; Pattinson, D.J.; Dulal, P.; Silk, S.E.; Marshall, J.M.; Dabbs, R.A.; Nugent, F.L.; Barrett, J.R.; Hjerrild, K.A.; Poulsen, L.; Jørgensen, T.; Brenner, T.; Baleanu, I.N.; Parracho, H.M.; Tahiri-Alaoui, A.; Whale, G.; Moyle, S.; Payne, R.O.; Minassian, A.M.; Higgins, M.K.; Detmers, F.J.; Lawrie, A.M.; Douglas, A.D.; Smith, R.; de Jongh, W.A.; Berrie, E.; ... view all 32 authors

Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for\ud malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under\ud cGMP... View more